22 May 2013
Keywords: phase, ii, ranolazine, data, published, cv, therapeutics
Article | 01 July 1999
CV Therapeutics' ranolazine has completed a Phase II trial whichdemonstrates the compound has efficacy in increasing exercise time in
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 May 1999
23 August 1999
21 May 2013
© 2013 thepharmaletter.com